Injection Immunotherapy for Inhalant Allergens

Middleton's Allergy: Principles and Practice: Eighth Edition

Volumn 2-2, Issue , 2014, Pages 1416-1437

  Nelson, Harold S ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927673043     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-08593-9.00088-7     Document Type: Chapter

References (235)

1. Noon L Prophylactic inoculation against hay fever. Lancet 1911, i:1572-1573.
2. Freeman J Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911, ii:814-817.
3. Nelson HS Some highlights of the first century of immunotherapy. Ann Allergy Asthma Immunol 2011, 107:417-421.
4. Frankland AW, Augustin R Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet 1954, i:1055-1057.
5. Lowell FC, Franklin W A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 1965, 273:675-679.
6. Franklin W, Lowell FC Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA 1967, 201:915-917.
7. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991, 302:265-269.
8. Varney VA, Tabbah K, Mavroleon G, Frew AJ Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003, 33:1076-1082.
9. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, (1).
10. Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001, 107:87-93.
11. Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997, 27:860-867.
12. Olsen OT, Larsen KR, Jacobsen L, Svendsen UG A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997, 52:853-859.
13. Zielen S, Kardoa P, Madonini E Steroid-sparing effects with allergen-specific immunotherapy in childen wih asthma: a randomized controlled trial. J Allergy Clin Immunol 2010, 126:942-949.
14. Blumberga G, Groes L, Haugaard L, Dahl R Steroid-sparing effect of subcutaneous SQ-standardized specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006, 61:843-848.
15. Abramson MJ, Puy RM, Weiner JM Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010, (8).
16. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996, 334:501-506.
17. Adkinson NF, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997, 336:324-331.
18. Ring J Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982, 107:597-602.
19. Zachariae H, Cramers M, Herlin T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venerol 1985, 114:48-54.
20. Seidenari S, Mosca M, Taglietti M, et al. Specific hyposensitization in atopic dermatitis. Dermatologica 1986, 172:229.
21. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006, 61:202-205.
22. Sears MR, Burrows B, Flannery EM, et al. Atopy in childhood: I. Gender and allergen related risks for development of hay fever and asthma. Clin Exp Allergy 1993, 23:941-948.
23. Peat JK, Tovey E, Mellis CM, et al. Importance of house dust mite and Alternaria allergens in childhood asthma. An epidemiological study in two climatic regions of Australia. Clin Exp Allergy 1993, 23:812-820.
24. Gergen PJ, Turkeltaub PC The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). J Allergy Clin Immunol 1992, 90:579-588.
25. Zock JP, Brunekreef B, Hazebroek-Kampschreur AA, Roosjen CW House dust mite allergen in bedroom floor dust and respiratory healthy of children with asthmatic symptoms. Eur Respir J 1994, 7:1254-1259.
26. Vervloet D, Charpin D, Haddi E, et al. Medication requirements and house dust mite exposure in mite-sensitive asthmatics. Allergy 1991, 46:554-558.
27. Valletta EA, Comis A, Del Col G, et al. Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposure. Allergy 1995, 50:366-369.
28. Peroni DG, Boner AL, Vallone G, et al. Effective allergen avoidance at high altitude reduces allergen-induced bronchial hyperresponsiveness. Am J Respir Crit Care Med 1994, 149:1442-1446.
29. Simon HU, Grotzer M, Nikokaizik WH, et al. High altitude climate therapy reduces peripheral blood T lymphocyte activation, eosinophilia, and bronchial obstruction in children with house dust mite allergic asthma. Pediatr Pulmonol 1994, 17:304-311.
30. Patterson R Clinical efficacy of allergen immunotherapy. J Allergy Clin Immunol 1979, 64:155-158.
31. Custovic A, Taggart SCO, Woodcock A House dust mite and cat allergen in different indoor environments. Clin Exp Allergy 1994, 24:1164-1168.
32. Ingram JM, Sporik R, Rose G, et al. Quantitative assessment of exposure to dog (Can f I), and cat (Fel d I) allergens: relation to sensitization and asthma in children living in Los Alamos, New Mexico. J Allergy Clin Immunol 1995, 96:449-456.
33. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, et al. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994, 93:556-566.
34. Hedlin G, Graff-Lonnevig V, Heilbron H, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991, 87:955-964.
35. Salvaggio J, Aukrust L Mold-induced asthma. J Allergy Clin Immunol 1981, 68:327-346.
36. O'Hollaren MT, Yunginger JW, Offord KP, et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991, 324:359-363.
37. Salvaggio JE, Burge HA, Chapman JA Emerging concepts in mold allergy: what is the role of immunotherapy?. J Allergy Clin Immunol 1993, 92:217-222.
38. Yunginger JW, Jones RT, Gleich GJ Studies on Alternaria allergens. II. Measurement of the relative potency of commercial Alternaria extracts by the direct RAST and by RAST inhibition. J Allergy Clin Immunol 1976, 58:405-413.
39. Esch R Manufacturing and standardizing fungal allergen products. J Allergy Clin Immunol 2004, 113:210-215.
40. Dreborg S, Agrell B, Foucard T, et al. A double-blind, multicenter immunotherapy trial in children using a purified and standardized Cladosporium herbarum preparation. Allergy 1986, 41:131-140.
41. Malling H-J, Dreborg S, Weeke B Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986, 41:507-519.
42. Horst M, Hejjaoui A, Horst V, et al. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990, 85:460-472.
43. Kuna P, Kaczmarck J, Kupezyk M Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol 2011, 127:502-508.
44. Arruda LK, Vailes LD, Ferriani VPL, et al. Cockroach allergens and asthma. J Allergy Clin Immunol 2001, 107:419-428.
45. Patterson MI, Slater JE Characterization and comparison of commercially available German and American cockroach allergen extracts. Clin Exp Allergy 2002, 32:721-727.
46. Slater JE, James R, Pongracie JA, et al. Biological potency of German cockroach allergen extracts determined in an inner city population. Clin Exp allergy 2007, 37:1033-1039.
47. Sastre J, Fernandez-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003, 111:985-994.
48. Fontana VJ, Salanitro AS, Wolfe HI, Moreno F Bacterial vaccine and infectious asthma. JAMA 1965, 193. 895-890.
49. 2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010, 65:1525-1530.
50. Esch RF. Specific immunotherapy in the U.S.A. General concept and recent initiatives. Arbeiten aus dem Paul-Ehrlich-Institut. Band 94. 10th International Paul Ehrlich Seminar, Lubeck, 2002. p. 17-23.
51. Cox L, Nelson H, Lockey R Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127:S1-55.
52. Nelson HS Multi-allergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009, 123:763-769.
53. Johnstone DE, Crump L Value of hyposensitization therapy for perennial bronchial asthma in children. Pediatrics 1961, 27:39-44.
54. Reid MJ, Moss RB, Hsu YP, et al. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986, 78:590-600.
55. Norman PS, Lichtenstein LM The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978, 61:370-377.
56. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997, 99:450-453.
57. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001, 31:1392-1397.
58. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitzed subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001, 31:1295-1302.
59. Limb SL, Brown KC, Wood RA, et al. Long term immunologic effects of aeroallergen immunotherapy. Int Arch Allergy Immunol 2006, 140:245-251.
60. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol 2002, 109:251-256.
61. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect on seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62:943-948.
62. Ebner C, Kraft D, Ebner H Booster immunotherapy (BIT). Allergy 1994, 49:38-42.
63. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
64. Eng PA Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006, 61:198-201.
65. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996, 51:30-33.
66. Kelso JM, Jones RT, Tellez R, Yunginger JW Oral allergy syndrome successfully treated with pollen immunotherapy. Ann Allergy Asthma Immunol 1995, 74:391-396.
67. Asero R How long does the effect of birch pollen injection SIT on apple allergy last?. Allergy 2003, 58:435-438.
68. Bucher X, Pichler WJ, Dahinden CA, Helbling A Effect of tree pollen specific subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004, 59:1272-1276.
69. Rak S, Heinrich C, Jacobsen L, et al. A double-blinded, comparative study of the effects of short preseason specific immntherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001, 108:921-928.
70. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008, 121:227-232.
71. Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retropective, matched cohort study. Ann Allergy Asthma Immunol 2010, 104:79-85.
72. Bousquet J, Maasch H, Martinot B, et al. Double-blind, placebo-controlled immunotherapy with mixed grass pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988, 82:439-446.
73. Ewbank PA, Murray J, Sanders K, et al. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003, 111:155-161.
74. Nanda A, O'Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004, 114:1339-1344.
75. Lent A, Harbeck R, Strand M, et al. Immunological response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 2006, 118:1249-1256.
76. Nish WA, Charlesworth EN, Davis TL, et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994, 93:484-493.
77. Iliopoulos O, Proud D, Adkinson NF, et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991, 87:855-866.
78. Van Bever HP, Bosmans J, De Clerck LS, Stevens WJ Modification of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus) or grass pollen. Allergy 1988, 43:378-385.
79. Pichler CE, Helbling A, Pichler WJ Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001, 56:301-306.
80. Furin MJ, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991, 88:27-32.
81. Rak S, Bjornson A, Hakanson L, et al. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991, 88:878-888.
82. Wilson DR, Iani AMA, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001, 31:1705-1713.
83. Wilson DR, Nuri-Aria KT, Walker SM, et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001, 107:971-976.
84. Nouri-Aria KT, Pilette C, Jacobson MR, et al. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effects of immunotherapy. J Allergy Clin Immunol 2005, 116:73-79.
85. Norman PS, Lichtenstein LM, Marsh DG Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol 1981, 68:460-470.
86. Sherman WB, Stull A, Cooke RA Serologic changes in hay fever cases treated over a period of years. J Allergy 1940, 11:225-244.
87. Cooke RA, Barnard JH, Hebald S, Stull A Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever). J Exp Med 1935, 62:733-750.
88. Alexander HL, Johnson MC, Bukantz SC Studies on correlation between symptoms of ragweed hay fever and titer of thermostable antibody. J Allergy 1948, 19:1-8.
89. Djurup R, Osterballe O IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy. Allergy 1984, 39:433-441.
90. Shamji MH, Ljorring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2011, 67:217-226.
91. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011, 127:509-516.
92. Sadan N, Rhyne MB, Mellits ED, et al. Immunotherapy of pollinosis in children. Investigation of the immunologic basis of clinical improvement. N Engl J Med 1969, 280:623-627.
93. Lichtenstein LM, Levy DA Is desensitization for ragweed hay fever immunologically specific?. Int Arch Allergy 1972, 42:615-626.
94. Hsieh KH Decreased production of interleukin-2 receptors after immunotherapy to house dust. J Clin Immunol 1988, 8:171-177.
95. Evans R, Pence H, Kaplan H, Rocklin RE The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest 1976, 57:1378-1385.
96. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980, 302:1214-1219.
97. Tamir R, Castracane JM, Rocklin RE Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis. J Allergy Clin Immunol 1987, 79:591-598.
98. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003, 33:1205-1214.
99. Lin YL, Shieh CC, Wang JY The functional insufficiency of human CD4+CD25high T-regulatory cells in allergic asthma is subjected to TNF-alpha modulation. Allergy 2008, 63:67-74.
100. Francis NJ, Till SJ, Durham SR Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003, 111:11255-11261.
101. Gardner LM, Thien FC, Douglass JA, et al. Induction of T regulatory cells by standardized house dust mite immunotherapy: an increase in CD4+CD25 interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 2004, 34:1209-1219.
102. Savolainen J, Jacobsen L, Valovirta E Sublingual immunotherapy in children modulates allergen induced expression of cytokine mRNA in PBMC. Allergy 2006, 61:1184-1190.
103. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993, 92:644-651.
104. Wambre E, DeLong JH, James EA, et al. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol 2012, 129:544-551.
105. Gabrielsson S, Soderlund A, Paulie S, et al. Specific immunotherapy prevents increased levels of allergen-specific IL-4 and IL-13-producing cells during pollen season. Allergy 2001, 56:293-300.
106. Lack G, Nelson HS, Amran D, et al. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma production in CD4+ T cells. J Allergy Clin Immunol 1997, 99:530-538.
107. Majori M, Caminati A, Corradi M, et al. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy 2000, 30:341-347.
108. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996, 97:1356-1365.
109. Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997, 99:254-260.
110. Wang JY, Lei HY, Hsieh KH The effect of immunotherapy on interleukin-1 and tumor necrosis factor production of monocytes in asthmatic children. J Asthma 1992, 29:193-201.
111. Wantke F, Gotz M, Janisch R Spontaneous histamine release in whole blood in patients before and after 4 months of specific immunotherapy. Clin Exp Allergy 1993, 23:992-995.
112. Kuna P, Alam R, Kuzminska B, Rozniecki J The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol 1989, 83:816-824.
113. Brunet C, Bedard PM, Lavoie A, et al. Allergic rhinitis to ragweed pollen. II. Modulation of histamine-releasing factor production by specific immunotherapy. J Allergy Clin Immunol 1992, 89:87-94.
114. Liao TN, Hsieh KH Altered production of histamine-releasing factor (HRF) activity and responsiveness to HRF after immunotherapy in children with asthma. J Allergy Clin Immunol 1990, 86:894-901.
115. Hsieh KH, Ng CK Increased plasma platelet activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet activating factor after immunotherapy. J Allergy Clin Immunol 1993, 91:60-67.
116. Gagro A, Rabatic S, Trescec A, et al. Expression of lymphocytes FcεRII/CD23 in allergic children undergoing hyposensitization. Int Arch Allergy Immunol 1993, 101:203-208.
117. Kljaic-Turkalj M, Cvoriscec B, Tudoric N, et al. Decrease in CD23+ B lymphocytes and clinical outcome in asthmatic patients receiving specific rush immunotherapy. Int Arch Allergy Immunol 1996, 111:188-194.
118. Jung CM, Prinz JC, Rieber EP, Ring J A reduction in allergen-induced FcεR2/CD23 expression on peripheral B cells correlates with successful hyposensitization in grass pollinosis. J Allergy Clin Immunol 1995, 95:77-87.
119. Hakansson L, Heinrich C, Rak S, Venge P Activation of B-lymphocytes during pollen season. Effect of immunotherapy. Clin Exp Allergy 1998, 28:791-798.
120. Plewako H, Arvidsson M, Oancca I, et al. The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients. Clin Exp Allergy 2004, 34:1862-1867.
121. Bellinghausen I Modification of the innate immune function of dendritic cells by allergen-specific immunotherapy. Clin Exp Allergy 2010, 40:12-14.
122. Tversky JR, Bieneman AP, Chichester KL, et al. Subcutaneous allergen immunotherapy restores human dendritic cell innate immune function. Clin Exp Allergy 2010, 40:94-102.
123. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007, 120:707-713.
124. Lofkvist T, Agrell B, Dreborg S, Svensson G Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis. Allergy 1994, 49:100-107.
125. Finegold I Immunotherapy: when to initiate treatment in children. Allergy Asthma Proc 2007, 28:698-705.
126. Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988, 82:971-977.
127. Nelson HS, Areson J, Reisman R A prospective assessment of the remote practice of allergy. Comparison of the diagnosis of allergic disease and the recommendations for allergen immunotherapy by board-certified allergists and a laboratory performing in vitro assays. J Allergy Clin Immunol 1993, 92:380-386.
128. Yoo T-J, Spitz E, McGerity JL Conifer pollen allergy: studies of immunogenicity and cross antigenicity of conifer pollens in rabbit and man. Ann Allergy 1975, 34:87-93.
129. Martin BG, Mansfield LE, Nelson HS Cross-allergenicity among the grasses. Ann Allergy 1985, 54:99-104.
130. Davies JM, Bright ML, Rolland JM, et al. Bahia grass pollen specific IgE is common in seasonal rhinitis patients but has limited cross-reactivity with ryegrass. Allergy 2005, 60:251-255.
131. Asero R, Weber B, Mistrello G, et al. Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: analysis of the allergenic differences between short and giant ragweed. J Allergy Clin Immunol 2005, 116:1036-1041.
132. Weber RW Cross-reactivity of pollen allergens: impact on allegen immunotherapy. Ann Allergy Asthma Immunol 2007, 99:203-211.
133. Esch RE Role of proteases on the stability of allergic extracts. Regulatory control and standardization of allergenic extracts 1990, 171-177. Gustav Fischer Verlag, Stuttgart. R. Klein (Ed.).
134. Nelson HS, Iklé D, Buchmeier A Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 1996, 98:382-388.
135. Grier TJ, LeFevre DM, Duncan EA, Esch RE Stability of standardized grass, dust mite, cat and short ragweed allergens after mixing with mold or cockroach extracts. Ann Allergy Asthma Immunol 2007, 99:151-160.
136. Grier TJ, LeFevre DM, Duncan EA, Esch RE Stability and mixing compatibility of dog epithelia and dog dander allergens. Ann Allergy Asthma Immunol 2009, 103:411-417.
137. Johnstone DE, Dutton A The value of hyposensitization therapy for bronchial asthma in children-a 14-year study. Pediatrics 1968, 42:793-802.
138. Cox L, Jacobsen L Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009, 103:451-460.
139. Nelson HS The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol 2000, 106:41-45.
140. Majchel AM, Proud D, Friedhoff L, et al. The nasal response to histamine challenge: effect of the pollen season and immunotherapy. J Allergy Clin Immunol 1992, 90:85-91.
141. Creticos PS, Adkinson NF, Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J Clin Invest 1985, 76:2247-2253.
142. Creticos PS, Marsh DG, Proud D, et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989, 84:197-205.
143. Van Metre TE, Adkinson NF, Amodio FJ, et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1979, 66:500-513.
144. Haugaard L, Dahl R, Jacobsen L A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993, 91:709-722.
145. Frew AJ, Powell RJ, Corrigan CJ, et al. Efficacy and safety of specific imunotheapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:319-328.
146. Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004, 59:45-53.
147. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122:951-960.
148. Bodtger U, Poulsen LK, Jacobi HH, et al. The safety and efficacy of subcutaneous birch pollen immunotherapy-a one-year, randomized, double-blind, placebo-controlled study. Allergy 2002, 57:297-303.
149. Vailes L, Sridhara S, Cromwell O, et al. Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products. J Allergy Clin Immunol 2001, 107:641-646.
150. Leavengood DC, Renard RL, Martin BG, Nelson HS Cross allergenicity among grasses determined by tissue threshold changes. J Allergy Clin Immunol 1985, 76:789-794.
151. Nelson HS Effect of preservatives and conditions of storage on the potency of allergy extracts. J Allergy Clin Immunol 1981, 67:64-69.
152. Van Metre TE, Rosenberg GL, Vaswani SK, et al. Pain and dermal reaction caused by injected glycerin in immunotherapy solutions. J Allergy Clin Immunol 1996, 97:1033-1039.
153. Moore M, Tucker M, Grier T, Quinn J Effects of summer mailing on in vivo and in vitro relative potencies of standardized timothy grass extract. Ann Allergy Asthma Immunol 2010, 104:147-151.
154. Malling HJ, Weeke B Position paper: immunotherapy. Allergy 1993, 48(Suppl. 14):9-35.
155. Van, Metre TE, Jr, Adkinson NF, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982, 69:181-193.
156. Portnoy J, Bagstad K, Kanarek H, et al. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy 1994, 73:409-418.
157. Bousquet J, Hejjaoui A, Dhivert H, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989, 83:797-802.
158. Moyer DB, Nelson HS Use of modified radioallergosorbent testing in determining initial immunotherapy doses. Otolaryngol Head Neck Surg 1985, 93:335.
159. Sharkey P, Portnoy J Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol 1996, 76:175-180.
160. Hejjaoui A, Dhivert H, Michel FB, Bousquet J Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990, 85:473-479.
161. Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules and Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005, 116:109-118.
162. Mauro M, Russello M, Alesina R, et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol 2006, 38:31-34.
163. Lin MS, Tanner E, Lynn J, Friday GA Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993, 71:557-562.
164. Tinkelman DG, Cole WQ, Tunno J Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995, 95:8-14.
165. Tankersley MS, Butler KK, Butler WK, Goetz DW Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000, 106:840-843.
166. Kelso MJ The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004, 92:225-227.
167. Webber CM, Calabria CW Assessing the safety of subcutaneous immunotherapy dose adjustments. Ann Allergy Asthma Immunol 2010, 105:369-375.
168. Dolz I, Martinez-Cocerac C, Bartolone JM, Cimmara M A double-blind, placebo-controlled study of immunotherapy with grass pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996, 51:489-500.
169. Tabar AI, Arroabarren E, Echechipia S, et al. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011, 127:57-63.
170. Lockey RF, Benedict IM, Turkeltaub PC, Bukantz SC Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987, 79:660-677.
171. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993, 92:6-15.
172. Bernstein DI, Wanner M, Borish L, Liss GM Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004, 113:1129-1136.
173. Bernstein DL, Epstein T, Murphy-Barendts K, Liss GM Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010, 104:530-535.
174. Confino-Cohen R, Goldberg A Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol 2010, 104:73-78.
175. Scranton SE, Gonzalez EG, Waibei KH Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol 2009, 123:493-498.
176. Nielsen L, Johnsen CR, Mosbech H, et al. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996, 97:1207-1213.
177. Ohashi Y, Nakai Y, Muraata K Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006, 96:600-605.
178. Wohn S, Gamper S, Hemmer W, et al. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007, 144:137-142.
179. Stein MR, Brown GL, Lima JE, et al. A laboratory evaluation of immune complexes in patients on inhalant immunotherapy. J Allergy Clin Immunol 1978, 62:211-216.
180. Levinson AI, Summers RJ, Lawley TJ, et al. Evaluation of the adverse effects of long-term hyposensitization. J Allergy Clin Immunol 1978, 62:109-114.
181. Francis N Abortion after grass pollen injection. J Allergy 1941, 12:559-563.
182. Metzger WJ, Turner E, Patterson R The safety of immunotherapy during pregnancy. J Allergy Clin Immunol 1978, 61:268-272.
183. Shaikh WA A retrospective study on the safety of immunotherapy in pregnancy. Clin Exp Allergy 1993, 23:857-860.
184. Lower T, Henry J, Mandik L, et al. Compliance with allergen immunotherapy. Ann Allergy 1993, 70:480-482.
185. Cohn JR, Pizzi A Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993, 91:734-737.
186. Tinkelman D, Smith F, Cole WQ, Silk HJ Compliance with an allergen immunotherapy regimen. Ann Allergy Asthma Immunol 1995, 74:241-246.
187. Norman PS, Winkenwerder WL, D'Lugoff BC Controlled evaluations of repository therapy in ragweed hay fever. J Allergy 1967, 39:82-92.
188. Norman PS, Winkenwerder WL, Lichtenstein LM Trials of alum-precipitated pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1972, 50:31-44.
189. Nelson HS Long-term immunotherapy with aqueous and aluminum-precipitated grass extracts. Ann Allergy 1980, 45:333-337.
190. DuBuske LH, Frew A, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011, 32:239-247.
191. Hendrix SG, Patterson R, Zeiss GR, et al. A multi-institutional trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1980, 66:486-494.
192. Corrigan CJ, Kettner J, Doemer C, Cromwell O Efficacy and safety of preseasonally-specific immunotherapy with an aluminum-adsorbed six-grass pollen allergoid. Allergy 2005, 60:801-807.
193. Casanovas M, Sastre J, Fernandez-Nieto M, et al. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy 2005, 35:1377-1383.
194. Casanovas M, Martin R, Jimenez C, et al. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol 2006, 139:153-158.
195. Hoiby AS, Strand V, Robinson DS, et al. Efficacy, safety and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double blind, placebo-contrrolled study. Clin Exp Allergy 2010, 40:1062-1070.
196. Pfaar O, Robinson DS, Sager A, Emuzyte R Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 2010, 88:1614-1621.
197. Henmar H, Lund G, Lund L, et al. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol 2008, 153:316-323.
198. Basomba A, Tabar AI, de Roas DHF, et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 2002, 109:943-948.
199. Chapman MD, Smith AM, Vailes LD, et al. Recombinant allergens for diagnosis and therapy of allergic disease. J Allergy Clin Immunol 2000, 106:409-418.
200. Norman PS, Winkenwerder WL, Lichtenstein LM Immunotherapy of hay fever with ragweed antigen E: comparison with whole pollen extract and placebo. J Allergy 1968, 42:91-108.
201. Osterballe O Immunotherapy with grass pollen major allergens. Clinical results from a prospective 3-year double blind study. Allergy 1982, 37:379-388.
202. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005, 116:608-613.
203. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122:951-960.
204. Yssel H, Fasler S, Lamb J, de Vries JE Induction of non-responsiveness in human allergen-specific type 2 T helper cells. Curr Opinion Immunol 1994, 6:847-852.
205. Michael JG, Litwin A, Hasert V, Pesce A Modulation of the immune response to ragweed allergens by peptic fragments. Clin Exp Allergy 1990, 20:669-674.
206. Wallner BP, Gefter ML Peptide therapy for treatment of allergic diseases. Clin Immunol Immunopathol 1996, 80:105-109.
207. Norman PS, Ohman JL, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996, 154:1623-1628.
208. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999, 93:222-231.
209. Moldaver D, Larché M Immunotherapy with peptides. Allegy 2011, 66:784-791.
210. Oldfield WL, Kay AB, Larche M Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthamtic subjects. J Immunol 2001, 167:1734-1739.
211. Verhoef A, Alexander C, Kay AB, Larche M T cell epitope immunotherapy induces a CD 4+ T cell population with regulatory activity. PLOS Med 2005, 2:253-261.
212. Alexander C, Tarzi M, Larche M, Kay AB The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005, 60:1269-1274. '.
213. http://www.circassia.co.uk.
214. Gafvelin G, Thunberg S, Kronqvist M, et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005, 38:59-66.
215. Purohit A, Niederberger V, Kronqvist M, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Allergy 2008, 38:1514-1525.
216. Valenta R, Niespodziana K, Focke-Tejkl M, et al. Recombinant allergens: what does the future hold?. J Allergy Clin Immunol 2011, 127:860-864.
217. Asturias JA, Ibarrola I, Arilla MC, et al. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 2009, 39:1088-1098.
218. Ball T, Linhart B, Sonneckk K, et al. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy 2009, 64:569-580.
219. Gerstmayr M, Ilk N, Schabussova I, et al. A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10 producing regulatory T cells. J Immunol 2007, 179:7270-7275.
220. Saxon A, Kepley C, Zhang K "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. J Allergy Clin Immunol 2008, 121:320-325.
221. Nguyen TH, Stokes JR, Casale TB Future forms of immunotherapy and immunomodulators in allergic disease. Immunol Allergy Clin N Am 2011, 31:343-365.
222. Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998, 161:7054-7062.
223. Van Uden J, Raz E Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol 1999, 104:902-910.
224. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000, 106:124-134.
225. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445-1455.
226. Busse W, Gross G, Korenblat P, et al. Phase 2/3 study of the novel vaccine Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate AIC (Tolamba) in ragweed-allergic adults. Late-breaking abstracts. AAAAI Annual Meeting, Miami Beach, Fla., March 2006.
227. Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunoatherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009, 39:562-570.
228. Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011, 41:1305-1312.
229. Renner WA Cytos Biotechnology presents novel Toll-like receptor 9 agonist CYT003-QβG10 for the treatment of allergic asthma at the 2010 Annual Conference of the European Respiratory Society http://www.cytos.com.
230. Senti G, Vavricka BMP, Edrmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008, 105:17908-17912.
231. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009, 124:997-1002.
232. Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012, 129:128-135.
233. Agostinis F, Forti S, Berardino D Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 2010, 65:410-411.
234. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006, 117:134-140.
235. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010, 125:383-389.